AGK
Overview
AGK (Acylglycerol Kinase) encodes a lipid kinase involved in mitochondrial function and lipid metabolism. In cancer genomics, AGK has been identified as one of the most common 5’ fusion partners of BRAF in a tumor-agnostic landscape analysis, making it relevant as a recurrent structural driver across multiple tumor types.
Alterations observed in the corpus
- AGK::BRAF fusion identified as the third most common 5’ fusion partner in a tumor-agnostic analysis of 97,024 MSK-sequenced samples, accounting for 6% (N=12) of all BRAF fusion-positive tumors spanning 52 histologies PMID:38922339.
Cancer types (linked)
- AGK::BRAF fusions were detected across multiple histologies in a tumor-agnostic study; specific cancer type breakdown for AGK was not individually reported PMID:38922339.
Co-occurrence and mutual exclusivity
- BRAF fusions (including AGK::BRAF) are mutually exclusive with other MAPK pathway activating alterations in the MSK BRAF fusion cohort PMID:38922339.
Therapeutic relevance
- BRAF fusions including AGK::BRAF are class II alterations that activate MAPK signaling via constitutive dimerization and may be targetable with MEK inhibitors; overall ORR to available MAPK therapies in BRAF fusion-positive tumors is lower than for ALK/ROS1/RET fusions (60-80%) PMID:38922339.
Open questions
- The histology-specific distribution and clinical behavior of AGK::BRAF specifically (vs. other BRAF fusion partners) has not been characterized PMID:38922339.
Sources
This page was processed by crosslinker on 2026-05-04.